Therapy for metastatic ESFT: Is it time to ask new questions?

Pediatric Blood and Cancer

Volumn 49, Issue 2, 2007, Pages 115-116

  Snyder, Kristen M ^a   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; EWING SARCOMA; HUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; MULTICENTER STUDIES; NEUROECTODERMAL TUMORS, PRIMITIVE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; SARCOMA, EWING'S; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 34447261437     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21238     Document Type: Note

References (12)

1. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694-701.
2. Evans RG, Nesbit ME, Gehan EA, et al. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: A report from the second intergroup study. J Clin Oncol 1991;9:1173-1180.
3. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11:1911-1918.
4. Al-Faris N, Al Harbi T, Goia C, et al. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic relapsed Ewing sarcoma? Pediatr Blood Cancer (Epub ahead of print; 29 Jan 2007).
5. Burke M, Walterhouse D, Jacobsohn D, et al. Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer (Epub ahead of print; 6 April 2007).
6. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000;342: 1069-1076.
7. Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001;19: 2812-2820.
8. Burdach S, Meyer-Bahlburg A, Laws HJ, et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: Results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003;21:3072-3078.
9. Ek ET, Choong PF. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev Anticancer Ther 2006;6:225-237.
10. Krupica T, Jr., Fry TJ, Mackall CL. Autoimmunity during lymphopenia: A two-hit model. Clin Immunol 2006;120:121-128.
11. McAllister NR, Lessnick SL. The potential for molecular therapeutic targets in Ewing's sarcoma. Curr Treat Options Oncol 2005;6:461-471.
12. Dalai S, Berry AM, Cullinane CJ, et al. Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005;11:2364-2378.